Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a study of intratumoral AGI-134 alone or with pembrolizumab in unresectable or metastatic solid tumors
MOH_2018-05-14_002341Phase 2Recruiting
- Sponsor
- Agalimmune Ltd
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of AGI-134 and pembrolizumab in Nonhematologic neoplasms, colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Agalimmune Ltd. Primary endpoint: Safety and tolerability of AGI-134. Started Mar 2018; status: recruiting.
02
Drugs
AGI-134pembrolizumab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2018-05-14_002341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-14_002341.